Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Reasons for an Onc buyout or partnership…

<< Previous

Bullboard Posts

Next >>

Comment by TMAZZ21on Feb 01, 2023 12:43pm

210 Views

Post# 35259859

RE:Reasons for an Onc buyout or partnership…

Canda Fan or Notable

- Could Pfizer buy out also include license deal with pancreatic cancer, if that's the case wouldn't that be like taking the rug out from under Roche.

Does the 90 day blackout period inclusive of the pancreatic or can Roche do a separate license agree prior to the blackout period?

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland